American Journal of Therapeutics Accepts FLCCC Meta-Analysis Evidencing Promise of Ivermectin as Treatment for COVID-19

American Journal of Therapeutics Accepts FLCCC Meta-Analysis Evidencing Promise of Ivermectin as Treatment for COVID-19

That the editors in Frontiers in Pharmacology recently were scheduled to publish an important  and perhaps considered by some interests a controversial study authored by the research team at the Front Line COVID-19 Critical Care Alliance (FLCCC). Led by physicians Drs. Pierre Kory and Paul E. Marik, the group of committed physicians/researchers work on the front lines caring for patients as critical care physicians while advocating tirelessly for an open and honest scientific discussion about the results of numerous studies involving the generic drug ivermectin and its possible use to address COVID-19. Their meta-analysis of ivermectin studies was subjected to a particularly rigorous and protracted review process over at Frontiers in Pharmacology and was even scheduled to be published with an abstract online, but somehow, some way, an unnamed expert got involved last minute after the reviews were done and the manuscript was ready for prime time. The publisher cancelled. But just recently, another prominent medical journal, the American Journal of Therapeutics, accepted the manuscript. The world will soon review the numerous studies evidencing positive results, despite rampant cens...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee